Dec-01-15 Antibe Therapeutics Reports Q2 2016 Interim Financial and Operating Results and Appoints New CFO
Nov-16-15 Antibe Enters into a GUD Product Licensing Agreement with Knight Therapeutics
Oct-16-15 Antibe Therapeutics Closes Strategic Transactions
Oct-08-15 Antibe Therapeutics’ Lead Drug Shows Promising Effects in Alveolar Bone Loss Study
Oct-06-15 Antibe Therapeutics Announces Strategic Transactions
Aug-27-15 Antibe Therapeutics Reports Q1 2016 Interim Financial and Operating Results and a Further Update on its Validation Studies
Aug-10-15 Antibe Announces Completion of Phase I Studies of ATB-346 and an Update on its Validation Studies
Jul-28-15 Antibe Therapeutics Reports Year-End Financial and Operating Results
Jul-20-15 Antibe Therapeutics Announces Addition of Aspirin Derivative to its Product Pipeline and Provides an Update on Validation Studies
Jul-13-15 Antibe Therapeutics Announces Change in CFO Position and Granting of Employee Stock Options
May-05-15 Antibe Therapeutics Announces Administrative Items and Congratulates Dr. John Wallace on Publication in Nature Reviews
Apr-17-15 Antibe Therapeutics Announces Additional Validation Data on ATB-346
Apr-09-15 Antibe Therapeutics Completes Final Closing of Non-Brokered Private Placement Bringing Total Proceeds to $1,250,000
Apr-01-15 Antibe Therapeutics Raises $786,000 in First Tranche of Non-Brokered Private Placement
Mar-11-15 Antibe Therapeutics Provides an Update on its Data Review and Corporate Strategy
Feb-27-15 Antibe Therapeutics Reports Q3 2015 Interim Financial and Operating Results and Director Resignation
Feb-04-15 Antibe Therapeutics Announces No Material Change
Jan-16-15 Antibe Therapeutics Suspends its Phase I Clinical Trial Due to Safety Concerns
Dec-18-14 Antibe Therapeutics Announces Appointment of Canadian Rheumatologist J. Carter Thorne to its Clinical Advisory Board
Dec-16-14 Antibe Therapeutics Announces Appointment of US-Based Investor Relations Consultant